Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ2 | P63252 | 1/20 | 0.55 |
| ▸ | POLQ | O75417 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367110 | 0.71 | KCNJ2 (1.00) | KCNJ2POLQLMNATSHRGAA | |
| SCHEMBL20142742 | 0.71 | KCNJ2 (1.00) | KCNJ2POLQLMNATSHRGAA | |
| SCHEMBL1008156 | 0.71 | KCNJ2 (0.41) | KCNJ2POLQLMNATSHRGAA | |
| SCHEMBL1008066 | 0.71 | SMN1; SMN2 (0.63) | LMNATSHRGAAMAPTPOLB | |
| SCHEMBL1006588 | 0.70 | POLQ (0.42) | KCNJ2POLQLMNATSHRGAA | |
| SCHEMBL1009641 | 0.70 | POLQ (0.41) | KCNJ2POLQLMNATSHRGAA | |
| SCHEMBL1890413 | 0.69 | MAPT (0.57) | POLQLMNATSHRGAAMAPT | |
| SCHEMBL1009354 | 0.69 | SMN1; SMN2 (0.63) | LMNATSHRMAPTPOLBTP53 | |
| SCHEMBL1008435 | 0.68 | LMNA (1.00) | POLQLMNATSHRGAANPSR1 | |
| SCHEMBL15708803 | 0.67 | LMNA (1.00) | POLQLMNATSHRGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | KCNJ2 200/4885POLQ 3429/4885LMNA 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.